CME’s CEO Just Sold 43% of His Shares Near a Record
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.
On Wednesday, November 18, 2026, CME Group (NASDAQ:CME | CME Price Prediction) chairman and CEO Terry Duffy sold 27,000 shares. The sale cut his direct stake from 62,442 shares to 35,442 shares. That works out to 43% of his directly held shares.
The Form 4 was filed around 5:06 p.m. ET on Thursday, November 19. It shows two blocks: 10,000 shares at a weighted average of $308.54 and 17,000 shares at $310.18. Together they come to roughly $8.36 million, at an average price near $309.57.
The sale came as CME, valued at $109.64 billion, reported record volume. He sold above later prices: shares fell 1.27% to close November 19 at $306.31, and an after-hours quote of $308.11 stayed below both sale prices.
What the Filing Shows
The filing lists only directly held common stock. It reports no indirect holdings and no options, so the 43% covers only that one category of his holdings.
The Rule 10b5-1 box is not checked. A 10b5-1 plan is a trading schedule set in advance, and the blank box only means this form reports no such plan. The filing also gives no reason for the sale.
Executives usually sell to diversify, pay taxes, or raise cash. Duffy also received share awards on March 15 and September 15, 2026, and those awards add to the holdings he sells from.
This is his third sale of 2026 and one of seven sales since August 2023. His sale prices have risen along with the stock, from $203.95 in August 2023 to $298.51 in May 2026.
The November sale was smaller than his 40,000-share sale in April 2024. The percentage is large because he held fewer shares directly going in. His last open-market purchase was about 2,000 shares at near $220 in November 2021.
Volume Still Drives Revenue
CME collects a fee on every futures and options contract traded, so volume drives revenue. When markets swing, hedgers and traders adjust positions more often, and more contracts change hands.
October average daily volume hit a record 30 million contracts[1], up 15% from a year earlier. Third-quarter revenue reached $1.7 billion[2], a record for that quarter. On the October 21[2] earnings call, Duffy said, “I am highly confident in the opportunities ahead of us.”
How Far CME Sits From Its Record
The record close is $326.46, set on March 2, 2026, and the intraday record of $329.16 came on March 3. Duffy’s average sale price was 5.2% below the record close, so the stock was close to its March record when he sold.
The stock was even closer on November 16, when it closed at $319.37, about 2% below the record. It then fell 2.45% on Tuesday and 0.42% on Wednesday, the day he sold. The November 19 close was 6.2% below the record. That still leaves a price-only gain of 12.2% from the $273.08 close on December 31, 2025, which excludes dividends.
What Investors Should Weigh Before CME’s Next Volume Report
The analysts’ average price target of $318.13 is above the November 19 close but below the 52-week high, so the room for further gains looks modest. Most of the case comes from income and steady fee growth.
The quarterly dividend is $1.30 per share. The ex-dividend date is December 11, and the payment date is December 30. CME has also paid an extra annual variable dividend in past years under a policy that began in 2012[3], although no future amount has been declared.
Volume could cool from record levels, and rival exchanges compete for the same trading. The 52-week low of $218.31 shows how far the shares can fall.
Two things to check are the next Form 4 and the next monthly volume report. If volume growth turns negative while Duffy keeps selling, the case for the stock weakens.
Contact [email protected] for any questions or corrections.








